UBS Adjusts Numbers on Amgen (AMGN); Tough ODAC for Xgeva
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $416.05 +0.20%
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 20
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 20
Join SI Premium – FREE
UBS maintains a 'Neutral' on Amgen (NASDAQ: AMGN) price target cut $1 to $69.
UBS analyst says, "Not surprisingly, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 12-1 that a favorable benefit-risk profile was not established for Xgeva in the prevention of bone metastases in high-risk prostate cancer patients. Most of the panel’s issues boiled down to whether there was any incremental benefit of treating sooner (in prevention) than later (in treatment of bone metastases, or SRE setting)...The silver lining here may be that limiting Xgeva usage to the SRE setting may ultimately result in a better perceived safety profile for Xgeva."
UBS lowers FY12 EPS estimate from $6.14 to $6.10 and FY13 from $6.75 to $6.69.
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $68.06 yesterday.
UBS analyst says, "Not surprisingly, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 12-1 that a favorable benefit-risk profile was not established for Xgeva in the prevention of bone metastases in high-risk prostate cancer patients. Most of the panel’s issues boiled down to whether there was any incremental benefit of treating sooner (in prevention) than later (in treatment of bone metastases, or SRE setting)...The silver lining here may be that limiting Xgeva usage to the SRE setting may ultimately result in a better perceived safety profile for Xgeva."
UBS lowers FY12 EPS estimate from $6.14 to $6.10 and FY13 from $6.75 to $6.69.
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $68.06 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
- Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation
- Info Edge India (INFOE:IN) PT Raised to INR1,260 at Macquarie
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT Change, FDARelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
